Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1466058

Exploration of Abrocitinib in the Treatment of Refractory Chronic Spontaneous Urticaria: A Case Series

Provisionally accepted
Na Du Na Du 1Dan Wang Dan Wang 2*Jingyi Yang Jingyi Yang 1Yiwen Zhang Yiwen Zhang 1Xinyan Lyu Xinyan Lyu 1Wei Min Wei Min 1*Sicheng Zhao Sicheng Zhao 3*
  • 1 Department of Dermatology and Venereology, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 2 Department of Dermatology and Venereology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu Province, China
  • 3 Department of Dermatology and Venereology, Suzhou Kowloon Hospital, Suzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    In clinical practice, some cases of chronic spontaneous urticaria (CSU) remain difficult to treat, with up to 40% of patients showing no response to even high (4-fold) daily doses of antihistamines.Approximately 30% of CSU patients fail to achieve complete control and relief through treatment with omalizumab and may require alternative therapies. Abrocitinib is a small-molecule oral JAK1 inhibitor that suppresses intracellular signaling of multiple key cytokines involved in inflammation cascades, and has shown beneficial effects in patients with mast cell activation disorders. We conducted a retrospective analysis of the diagnosis and treatment records of adult patients with refractory CSU who were treated with abrocitinib after inadequate response to omalizumab (defined as no response to 300 mg/4 weeks of omalizumab treatment for 6 months, followed by adjustment to 300 mg/2 weeks for a further 3 months without controlling symptoms). We also collected data on relevant treatment modalities, clinical outcomes, and adverse events. Among these patients, various treatment modalities failed to adequately control symptoms, but switching to abrocitinib significantly improved clinical outcomes. Therefore, abrocitinib may represent a new treatment option for patients with refractory CSU.

    Keywords: JAK inhibitors, Abrocitinib, Omalizumab, chronic spontaneous urticaria, Refractory urticaria, efficacy and safety

    Received: 18 Jul 2024; Accepted: 23 Sep 2024.

    Copyright: © 2024 Du, Wang, Yang, Zhang, Lyu, Min and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Dan Wang, Department of Dermatology and Venereology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu Province, China
    Wei Min, Department of Dermatology and Venereology, The First Affiliated Hospital of Soochow University, Suzhou, China
    Sicheng Zhao, Department of Dermatology and Venereology, Suzhou Kowloon Hospital, Suzhou, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.